CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
Recently developed calcitonin gene-related peptide (CGRP) receptor antagonistic molecules have shown promising results in clinical trials for acute treatment of migraine attacks. Drugs from the gepant class of CGRP receptor antagonists are effective and do not cause vasoconstriction, (one of the major limitations in the use of triptans); however their use had to be discontinued because of risk of